Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea-Reference-Cited by-同舟云学术

Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea

Published:2006-11 Issue:6 Volume:9 Page:299-305
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematol. Oncol.

Author:

Lazzarino M.,Morra E.,Brusamolino E.,Alessandrino E. P.,Orlandi E.,Pagnucco G.,Castagnola C.,Bernasconi P.,Merante S.,Bonfichi M.,Castelli G.,Canevari A.,Bernasconi C.

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference19 articles.

1. Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML)

2. Daunomycin, cytosin-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML

3. Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies

4. Combination Chemotherapy of Chronic

5. Application of bone marrow transplantation in chronic granulocytic leukaemia

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?;Journal of Cancer Research and Clinical Oncology;2017-06-17

2. Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post-remission bone marrow transplant →- a pilot study;European Journal of Haematology;2009-04-24

3. Successful Treatment of Accelerated and Blastic Phase of Chronic Myeloid Leukemia with High-Dose Interferon-alpha Combined with Hydroxyurea;Cancer Detection Prevention;1998-01

4. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia;Annals of Oncology;1997-02

5. The Enzyme Ribonucleotide Reductase: Target for Antitumor and Anti-HIV Therapy;Critical Reviews in Clinical Laboratory Sciences;1997-01